vs
ADMA BIOLOGICS, INC.（ADMA）与REPUBLIC BANCORP INC（RBCAA）财务数据对比。点击上方公司名可切换其他公司
ADMA BIOLOGICS, INC.的季度营收约是REPUBLIC BANCORP INC的1.5倍（$139.2M vs $94.3M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs 24.2%，领先11.3%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs 5.3%），REPUBLIC BANCORP INC自由现金流更多（$161.1M vs $34.6M），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs -11.5%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
肯塔基州共和银行是美国的一家区域性银行控股企业，提供零售及商业银行全品类服务，涵盖个人存贷款、企业融资、按揭产品及财富管理解决方案，主要服务肯塔基州及周边州的个人消费者和中小企业客户。
ADMA vs RBCAA — 直观对比
营收规模更大
ADMA
是对方的1.5倍
$94.3M
营收增速更快
ADMA
高出13.1%
5.3%
净利率更高
ADMA
高出11.3%
24.2%
自由现金流更多
RBCAA
多$126.6M
$34.6M
两年增速更快
ADMA
近两年复合增速
-11.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $94.3M |
| 净利润 | $49.4M | $22.8M |
| 毛利率 | 63.8% | — |
| 营业利润率 | 45.1% | 29.3% |
| 净利率 | 35.5% | 24.2% |
| 营收同比 | 18.4% | 5.3% |
| 净利润同比 | -55.9% | 20.0% |
| 每股收益（稀释后） | $0.20 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMARBCAA
| Q4 25 | $139.2M | $94.3M | ||
| Q3 25 | $134.2M | $93.5M | ||
| Q2 25 | $122.0M | $93.8M | ||
| Q1 25 | $114.8M | $135.8M | ||
| Q4 24 | $117.5M | $89.5M | ||
| Q3 24 | $119.8M | $88.1M | ||
| Q2 24 | $107.2M | $86.9M | ||
| Q1 24 | $81.9M | $120.3M |
净利润ADMARBCAA
| Q4 25 | $49.4M | $22.8M | ||
| Q3 25 | $36.4M | $29.7M | ||
| Q2 25 | $34.2M | $31.5M | ||
| Q1 25 | $26.9M | $47.3M | ||
| Q4 24 | $111.9M | $19.0M | ||
| Q3 24 | $35.9M | $26.5M | ||
| Q2 24 | $32.1M | $25.2M | ||
| Q1 24 | $17.8M | $30.6M |
毛利率ADMARBCAA
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
营业利润率ADMARBCAA
| Q4 25 | 45.1% | 29.3% | ||
| Q3 25 | 38.0% | 40.4% | ||
| Q2 25 | 35.1% | 43.0% | ||
| Q1 25 | 30.4% | 44.1% | ||
| Q4 24 | 32.6% | 25.8% | ||
| Q3 24 | 33.1% | 38.4% | ||
| Q2 24 | 36.6% | 37.0% | ||
| Q1 24 | 26.7% | 32.2% |
净利率ADMARBCAA
| Q4 25 | 35.5% | 24.2% | ||
| Q3 25 | 27.1% | 31.8% | ||
| Q2 25 | 28.1% | 33.5% | ||
| Q1 25 | 23.4% | 34.8% | ||
| Q4 24 | 95.2% | 21.2% | ||
| Q3 24 | 30.0% | 30.1% | ||
| Q2 24 | 29.9% | 29.0% | ||
| Q1 24 | 21.7% | 25.4% |
每股收益（稀释后）ADMARBCAA
| Q4 25 | $0.20 | — | ||
| Q3 25 | $0.15 | — | ||
| Q2 25 | $0.14 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.45 | — | ||
| Q3 24 | $0.15 | — | ||
| Q2 24 | $0.13 | — | ||
| Q1 24 | $0.08 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $220.0M |
| 总债务越低越好 | $72.1M | — |
| 股东权益账面价值 | $477.3M | $1.1B |
| 总资产 | $624.2M | $7.0B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMARBCAA
| Q4 25 | $87.6M | $220.0M | ||
| Q3 25 | $61.4M | $484.2M | ||
| Q2 25 | $90.3M | $484.8M | ||
| Q1 25 | $71.6M | $793.0M | ||
| Q4 24 | $103.1M | $432.2M | ||
| Q3 24 | $86.7M | $530.9M | ||
| Q2 24 | $88.2M | $400.1M | ||
| Q1 24 | $45.3M | $546.4M |
总债务ADMARBCAA
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ADMARBCAA
| Q4 25 | $477.3M | $1.1B | ||
| Q3 25 | $431.2M | $1.1B | ||
| Q2 25 | $398.3M | $1.1B | ||
| Q1 25 | $373.4M | $1.0B | ||
| Q4 24 | $349.0M | $992.0M | ||
| Q3 24 | $231.9M | $979.7M | ||
| Q2 24 | $188.3M | $955.4M | ||
| Q1 24 | $153.7M | $935.6M |
总资产ADMARBCAA
| Q4 25 | $624.2M | $7.0B | ||
| Q3 25 | $568.7M | $7.0B | ||
| Q2 25 | $558.4M | $7.0B | ||
| Q1 25 | $510.6M | $7.1B | ||
| Q4 24 | $488.7M | $6.8B | ||
| Q3 24 | $390.6M | $6.7B | ||
| Q2 24 | $376.4M | $6.6B | ||
| Q1 24 | $350.9M | $6.9B |
负债/权益比ADMARBCAA
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $168.2M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $161.1M |
| 自由现金流率自由现金流/营收 | 24.8% | 170.9% |
| 资本支出强度资本支出/营收 | 0.8% | 7.5% |
| 现金转化率经营现金流/净利润 | 0.72× | 7.37× |
| 过去12个月自由现金流最近4个季度 | $27.8M | $288.6M |
8季度趋势，按日历期对齐
经营现金流ADMARBCAA
| Q4 25 | $35.6M | $168.2M | ||
| Q3 25 | $13.3M | $33.3M | ||
| Q2 25 | $21.1M | $8.4M | ||
| Q1 25 | $-19.7M | $93.2M | ||
| Q4 24 | $50.2M | $149.0M | ||
| Q3 24 | $25.0M | $51.3M | ||
| Q2 24 | $45.6M | $4.0M | ||
| Q1 24 | $-2.2M | $71.2M |
自由现金流ADMARBCAA
| Q4 25 | $34.6M | $161.1M | ||
| Q3 25 | $-1.1M | $30.8M | ||
| Q2 25 | $18.7M | $5.2M | ||
| Q1 25 | $-24.4M | $91.6M | ||
| Q4 24 | $47.5M | $143.2M | ||
| Q3 24 | $24.0M | $49.8M | ||
| Q2 24 | $43.6M | $2.7M | ||
| Q1 24 | $-4.6M | $69.1M |
自由现金流率ADMARBCAA
| Q4 25 | 24.8% | 170.9% | ||
| Q3 25 | -0.8% | 32.9% | ||
| Q2 25 | 15.3% | 5.5% | ||
| Q1 25 | -21.2% | 67.4% | ||
| Q4 24 | 40.4% | 160.0% | ||
| Q3 24 | 20.0% | 56.5% | ||
| Q2 24 | 40.7% | 3.1% | ||
| Q1 24 | -5.6% | 57.5% |
资本支出强度ADMARBCAA
| Q4 25 | 0.8% | 7.5% | ||
| Q3 25 | 10.7% | 2.6% | ||
| Q2 25 | 2.0% | 3.5% | ||
| Q1 25 | 4.1% | 1.2% | ||
| Q4 24 | 2.3% | 6.5% | ||
| Q3 24 | 0.9% | 1.7% | ||
| Q2 24 | 1.9% | 1.5% | ||
| Q1 24 | 2.9% | 1.7% |
现金转化率ADMARBCAA
| Q4 25 | 0.72× | 7.37× | ||
| Q3 25 | 0.36× | 1.12× | ||
| Q2 25 | 0.62× | 0.27× | ||
| Q1 25 | -0.73× | 1.97× | ||
| Q4 24 | 0.45× | 7.84× | ||
| Q3 24 | 0.70× | 1.93× | ||
| Q2 24 | 1.42× | 0.16× | ||
| Q1 24 | -0.12× | 2.33× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
RBCAA
暂无分部数据
